Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172726 · ClinicalTrials.gov registry record · Phase 3
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
A Phase 3 study of Plaque Psoriasis, sponsored by Organon and.
- Active
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
- 19
- Study locations
NCT05172726 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Organon and. The registered enrollment target is 58 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower). The trial reports 19 study locations across 12 states.
The verdict
NCT05172726, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Organon and.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Conditions Studied
Interventions
- DRUG tapinarof cream, 1%
Study Locations (19)
Florida
- RM Medical Research - Miami Lakes
- San Marcus Research Clinic, Inc. - Miami Lakes
- Olympian Clinical Research - Tampa
Ontario
- Lynderm Research Inc. - Markham
- Alliance Clinical Trials - Waterloo
- Whitby Health Centre Dermatology Trials - Whitby
California
- First OC Dermatology - Fountain Valley
- Mission Dermatology Center - Rancho Santa Margarita
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
- Options Research Group - West Lafayette
Alberta
- Dermatology Research Institute Inc. - Calgary
- Rejuvenation Laser Dermatology Clinics - Edmonton
Arkansas
- Northwest Arkansas Clinical Trials Center, PLLC - Rogers
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Ohio
- Wright State Physicians Pharmacology Translational Unit - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05172726
The ClinicalTrials.gov registry entry for NCT05172726 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower). The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which tapinarof cream, 1% is the first listed.
NCT05172726 reports 19 study locations spanning 12 distinct geographic areas - top geographies include Florida, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT05172726 about?
NCT05172726 is a clinical study titled "Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects". This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
What is the current status of trial NCT05172726?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2021-12-02. Estimated completion is 2026-10.
What conditions does trial NCT05172726 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05172726?
The interventions under investigation include: tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05172726?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05172726 being conducted?
This trial has 19 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.